Our study showed that TMBIM1 regulates lysosomal pathways to promote the degradation of TGF-β type I receptors, suppress CS and inhibit HCC, thus providing a novel therapeutic strategy for preventing liver cancer and may shed light on other senescence-related diseases. This evidence concerns the gene TMBIM1 and hepatocellular carcinoma.